AstraZeneca PLC — Regulatory Filings 2016

Sep 26, 2016

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of September 2016

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_______

26 September 2016 16:00

Transaction by Person Discharging Managerial Responsibilities

Disclosure Rule DTR 3.1.4

On 26 September 2016, the interest of Sean Bohen, a person discharging managerial responsibilities, in the ordinary shares of AstraZeneca PLC changed as detailed below.

The change in interest relates to the vesting of an award of AstraZeneca American Depositary Shares (ADSs) made in September 2015 under the AstraZeneca Restricted Share Plan.

One ordinary share equals two ADSs.

After sufficient vested shares were withheld to satisfy certain tax obligations arising on the vesting, Mr Bohen has become beneficially entitled to and has received 12,385 ADSs into a personal brokerage account.

For tax purposes, the fair market value of the shares at vest was $33.97 per ADS being the closing price on the last trading day preceding the vesting day.

The attached notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

| 1 — a) | Details of the person discharging managerial responsibilities /
person closely associated — Name | Sean
Bohen | |
| --- | --- | --- | --- |
| 2 | Reason for the notification | | |
| a) | Position/status | Executive
Vice-President, Global Medicines Development and Chief Medical
Officer | |
| b) | Initial notification /Amendment | Initial
notification | |
| 3 | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | AstraZeneca
PLC | |
| b) | LEI | Not
applicable | |
| 4 | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted | | |
| a) | Description of the financial instrument, type of
instrument Identification
code | AstraZeneca PLC American Depositary Shares CUSIP: 046353108 | |
| b) | Nature of the transaction | Acquisition
of AstraZeneca American Depositary Shares pursuant to the vesting
of an award under the AstraZeneca Restricted Share
Plan | |
| | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | $33.97 | 12,385 |
| d) | Aggregated information - Aggregated volume - Price | Not applicable - single transaction | |
| e) | Date of the transaction | 26
September 2016 | |
| f) | Place of the transaction | New
York | |

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Respiratory and Autoimmunity, Cardiovascular and M e tabolic Diseases, and Oncology. The Company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com

CONTACTS

| Media Enquiries — Neil
Burrows | UK/Global | +44 203
749 5637 |
| --- | --- | --- |
| Vanessa
Rhodes | UK/Global | +44 203
749 5736 |
| Karen
Birmingham | UK/Global | +44 203
749 5634 |
| Rob
Skelding | UK/Global | +44 203
749 5821 |
| Jacob
Lund | Sweden | +46 8
553 260 20 |
| Michele
Meixell | US | +1 302
885 2677 |
| Investor Relations | | |
| UK | | |
| Thomas
Kudsk Larsen | | +44 203
749 5712 |
| Craig
Marks | Finance,
Fixed Income, M&A | +44
7881 615 764 |
| Nick
Stone | Respiratory
& Autoimmunity | +44 203
749 5716 |
| Henry
Wheeler | Oncology | +44 203
749 5797 |
| Christer
Gruvris | Infection
& Neuroscience | +44 203
749 5711 |
| US | | |
| Lindsey
Trickett | Cardiovascular
& Metabolic Diseases | +1 240
543 7970 |
| Mitchell
Chan | Oncology | +1 240
477 3771 |
| Toll-free | | +1 866
381 7277 |

Adrian Kemp

Company Secretary

AstraZeneca PLC

-ENDS-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 26 September 2016

By: /s/ Adrian Kemp

Name: Adrian Kemp

Title: Company Secretary

page break